Secondary Logo

Journal Logo

Rare mutations in renal sodium and potassium transporter genes exhibit impaired transport function

Welling, Paul A.

Current Opinion in Nephrology and Hypertension: January 2014 - Volume 23 - Issue 1 - p 1–8
doi: 10.1097/01.mnh.0000437204.84826.99
CIRCULATION AND HEMODYNAMICS: Edited by Matthew R. Weir and Roland C. Blantz
Free

Purpose of review Recent efforts to explore the genetic underpinnings of hypertension revealed rare mutations in kidney salt transport genes contribute to blood pressure (BP) variation and hypertension susceptibility in the general population. The current review focuses on these latest findings, highlighting a discussion about the rare mutations and how they affect the transport function.

Recent findings Rare mutations that confer a low BP trait and resistance to hypertension have recently been extensively studied. Physiological and biochemical analyses of the affected renal salt transport molecules [NKCC2 (SLC12A1), ROMK (KCNJ1), and NCC (SLC12A3)] revealed that most of the mutations do, in fact, cause a loss of transport function. The mutations disrupt the transport by many different mechanisms, including altering biosynthetic processing, trafficking, ion transport, and regulation.

Summary New insights into the genetic basis of hypertension have recently emerged, supporting a major role of rare, rather than common, gene variants. Many different rare mutations have been found to affect the functions of different salt transporter genes by different mechanisms, yet all confer the same BP phenotype. These studies reinforce the critical roles of the kidney, and renal salt transport in BP regulation and hypertension.

Department of Physiology, University of Maryland Medical School, Baltimore, Maryland, USA

Correspondence to Paul A. Welling, MD, Department of Physiology, University of Maryland Medical School, Baltimore, MD 21201, USA. Tel: +1 410 706 3851; e-mail: pwelling@umaryland.edu

Back to Top | Article Outline

INTRODUCTION

Hypertension is a common disease, affecting over a billion people on the planet. It has complex genetic and environmental underpinnings. Genes play a major role, with heritability of blood pressure (BP) levels estimated to be 30–35%. Environmental triggers, including high dietary sodium and low potassium intake, likely collude with the genetic factors to increase disease jeopardy. Recent efforts to explore the genetic underpinnings of the BP trait revealed that rare mutations in kidney salt transport genes contribute to BP variation in the general population, and play an important role in hypertension susceptibility. Here, we review these latest advances.

Back to Top | Article Outline

GENETICS OF THE VARIABLE BLOOD PRESSURE TRAIT AND HYPERTENSION

The ‘common disease–common variant’ hypothesis holds that the genetics of any particular common disease, like hypertension, can be explained by a few common gene variants specific to that disease. According to the theory, common single-nucleotide polymorphisms (SNPs), the largest source of genetic diversity in the human population, form the basis of most common disease alleles. Approximately 107 different SNPs are found at a frequency of 1–5% in the human population, accounting for 90% of human genetic variance. These SNPs arose early in human ancestry so that they are found in all modern populations throughout the globe.

Box 1

Box 1

In the last several years, numerous large, well controlled genomewide association studies (GWASs) have been performed [1–5], identifying many different interesting common hypertension susceptibility alleles. For example, a polymorphism in the promoter region of the endothelial nitric oxide synthase gene was recently indentified [1], reinforcing the contribution of vascular tone regulation in BP. Likewise, the discovery of a functional variant of the SPAK kinase (STK39), which regulates the thiazide-sensitive sodium chloride co-transporter [6], revealed the potential contribution of a multigene kinase network [7] and altered renal salt handling in essential hypertension [6,8▪]. Nevertheless, GWASs have not supported a major role for common variants in hypertension. Except for a few notable exceptions, like SPAK, it is not clear whether and how most variant alleles alter gene function, and their precise link to BP is not usually obvious. More importantly, the common variant alleles have a very small effect size on BP, and their frequency is too low to explain all but a small fraction of the genetic component of the disease.

As a result, the ‘common disease–rare variant’ hypothesis has gained favor [9]. This idea holds that common disease has highly heterogeneous underpinnings, attributable to any one of thousands of rare mutations. As the human population began to expand 10 000 years ago with the development of agriculture, the number of rare mutations in the population increased faster (∼100 mutations per generation) than the harmful ones could be eliminated by natural selection. Of course, once a harmful mutation arises, purifying selection keeps it rare in the population. Each individual has approximately half of a million rare variants; approximately 13 000 of these are found in gene coding regions, and it is estimated that 1% have functional effects [10▪▪]. According to the theory, a common disease may have disparate rare genetic origins because a gene or genes in a common pathway may harbor many different severe mutations that produce the same functional effect.

Ji et al.[11] explored the rare mutation and common disease hypothesis for hypertension, exploiting advances in high-throughput gene sequencing technologies to rapidly and efficiently find rare variants in the general population that might contribute to the BP trait. Their ingenious strategy was guided by the insights from Bartter's and Gitelman's syndromes, two rare recessive nephropathies characterized by renal salt-wasting and low BP [12]. Bartter's syndrome results from loss-of-function mutations in any one of the key salt transport molecules that are responsible for sodium chloride reabsorption in the thick ascending limb, including the sodium–potassium–two chloride cotransporter (NKCC2 or SLC12A1) and the ROMK channel (KCNJ1 or Kir1.1; Fig. 1). Gitelman's syndrome is caused by mutations in the thiazide-sensitive sodium chloride cotransporter, NCC (SLC12A3; Fig. 1). Because the prevalence of the syndromes predicts approximately 1% of the general population should be a carrier, Ji et al. reasoned that the heterozygous disease alleles might commonly impair renal salt reabsorption, and consequently confer a low BP trait.

FIGURE 1

FIGURE 1

They identified rare variants in NKCC2, ROMK, and NCC by exon sequencing in approximately 3000 individuals of the Framingham study cohort. Over a 100 different variants were found in the salt handling genes. The task was to accurately find the few relevant ones. Some of the variants had already been proven to cause inherited salt wasting (i.e. Bartter's or Gitleman's syndromes), making part of the job straightforward. Still, other variants had to be inferred to lead to loss of function. Algorithms have been developed to predict the likelihood that a sequence variant might impair function. Most of them, like the one used by Ji et al., are based on the simple assumption that changes in phylogenetically conserved residues will be damaging. An additional criterion that variants be present at a low frequency was used because harmful alleles are predicted to be under the pressure of purifying selection, and thus rare.

Remarkably, carriers for one of the proven or inferred mutations in NKCC2, NCC, or ROMK had a significantly lower BP compared with the rest of the cohort. The effect size was large, and carriers enjoyed protection against the development of hypertension throughout life. These observations established that rare mutations in renal salt handling genes do, in fact, commonly contribute to BP variation in humans. The study offered a glimpse into the genetic architecture of hypertension, revealing that rare mutations in salt transport genes are likely to play a substantial role in the disease. Just as predicted by the rare mutation–common disease hypothesis, many different rare mutations in a single salt transporting gene or a common pathway of salt transporting genes were found to confer the same BP phenotype.

Of course, interpretation of Ji et al.'s study hinged on knowing whether inferred variants actually lead to loss of function. The predictive power of the functional variant detection algorithms was, and still is, largely untested. Changes in evolutionarily conserved residues may not always cause loss of function. Conceivably, they might change or, even, increase function. For example, Conn's syndrome (aldosterone-producing adrenal adenomas and hypertension) can be caused by mutations in the highly conserved potassium selectivity filter of the KCNJ5 potassium channel [13], which changes the ion selectivity preference to sodium. This causes membrane depolarization, and stimulates aldosterone production and cell proliferation.

Fortunately, within 18 months of Ji et al.'s study, careful analyses of the inferred variants revealed at least 90% have a loss-of-function effect [14–16]. Collectively, the results of these studies indicate that rare mutations protect against hypertension by reducing the activity of renal salt reabsorptive genes. Genetic discovery followed by careful evaluation of the underlying biochemical and physiological mechanism has driven remarkable progress in nephrology and renal physiology in recent years. Studies on the hypertension resistance variants in ROMK, NKCC2, and NCC provide new insights into their biology.

Back to Top | Article Outline

HYPERTENSION RESISTANCE VARIANTS IN ROMK

ROMK, the product of the KCNJ1 gene and the founding member of the ‘inwardly rectifying’ (Kir-type) potassium channel family, has two important functions in the thick ascending limb that are essential for salt reabsorption [17]. The channel sets a positive transepithelial membrane potential, important for the paracellular reabsorption of cations. It also transports potassium into the lumen of the thick ascending limb to maintain an adequate supply of the ion to preserve the turnover of the potassium-dependent NKCC2 transporter. Without ROMK, the thick ascending limb cannot reabsorb salt [18].

Like other Kir channels, the assembly of four ROMK subunits forms a channel [17]. By homology to crystallized family members, each ROMK subunit contains two membrane domains, which flank a potassium selectivity filter. Intracellular N-terminal and C-terminal domains fold to create a large regulatory structure with a long extended pore. The surface of this cytoplasmic domain serves as a site for modulation by kinases, lipids, and trafficking machinery. Interestingly, each of the four inferred functional mutations involve residues within the cytoplasmic domain (Fig. 2).

FIGURE 2

FIGURE 2

Fang et al.[14] investigated the impact of the four inferred hypertension resistance variants in ROMK using Xenopus oocytes as an expression system. The oocyte system reliably and robustly expresses the wild-type channel, and has been used successfully to evaluate the consequence of many Bartter's disease mutations. Remarkably, all variants affected the channel function, but they did so by different mechanisms.

Two of the hypertension resistance mutations (R193P and H251Y) completely disrupted channel function by inhibiting cell-surface membrane expression. Channels bearing these mutations become arrested in their journey through the secretory pathway somewhere between the endoplasmic reticulum (ER) and the Golgi. Such a trafficking defect is commonly observed with misfolded polytopic membrane proteins. This type of mutation, usually referred to as a processing or ‘trafficking’ mutation, is the basis for many genetic diseases including cystic fibrosis [19], Bartter's syndrome, and Gitelman's syndrome [12]. Consistent with this idea, R193 and H251 are buried deep within the structure of the cytoplasmic domain (Fig. 2), and atomic resolution homology modeling predicts that the mutations should impair proper folding of the cytoplasmic domain. Misfolded proteins are usually retained in the ER or retrieved from the Golgi for anterograde traffic back to the ER, where they are degraded by ER-associated degradation (ERAD) machinery [20].

Misfolded proteins are recognized as ERAD substrates in a variety of different ways [20], including immature glycosylation status, exposure of hydrophobic residues, presence of degradation signals, or absence of forward trafficking motifs. Recent studies with a closely related channel, Kir 2.1, suggest a mechanism for coupling protein folding to an early forward trafficking step in the secretory pathway [21]. Export of these channels from the Golgi is determined by a conformational signal that is created once the cytoplasmic domains appropriately fold together and adopt a proper tertiary structure. Such a process provides a quality control step in the secretory pathway, ensuring only properly folded channels exit the Golgi for traffic to the cell surface. Misfolded Kir2.1 in the Golgi is targeted for anterograde traffic to the ER, where it is presumably degraded by ERAD. Further studies are required to determine whether a similar process is at play with ROMK and the R193P, H251Y variants.

The other mutations (P166S and R169H) change channel gating, conferring a negative regulatory property. Like the wild-type channel [22], these mutant channels require phosphatidylinositol 4,5 biphosphate (PIP2) to stay open. But in contrast to the wild-type channel, which binds PIP2 so tightly that it is resistant to regulated changes in PIP2 hydrolysis [23], the P166S and P169H mutant channels bind PIP2 weakly. Remarkably, the crystal structures of related Kir channels have been recently solved with PIP2 bound [24,25], revealing that the affected residues flank the two critical arginines in the PIP2-binding site (Fig. 2). Because the mutations reduce rather than eliminate PIP2 binding, the channels remain open until PIP2 levels are perturbed [14]. Indeed, in heterologous expression models, the mutant channels become inhibited upon activation of Gq-protein-coupled receptors, which induce PIP2 hydrolysis through activation of phospholipase C. The observations suggest that the effects of the mutations may be conditionally manifested depending on the activation of Gq-protein-coupled receptors in the thick ascending limb. For example, activation of the angiotensin II receptor (AT1R), which normally enhances sodium transport in the thick ascending limb, may inhibit these mutant ROMK channels and mute the angiotensin II response in the mutant carriers.

Back to Top | Article Outline

HYPERTENSION RESISTANCE VARIANTS IN NKCC2

NKCC2, a member of the electroneutral cation-chloride cotransporter family (SLC12A1), is responsible for reabsorbing sodium, chloride, and potassium from the tubule lumen of the thick ascending limb, and is the molecular target of loop-diuretic drugs [26]. By homology to crystallized amino acid–polyamine–organocation APC family members [27], NKCC2 is composed of 12 transmembrane helixes, which pack as two homologous domains with inverted symmetry to form the presumed ion translation pathway (Fig. 3a). The cytosolic N-terminal domain contains the binding sites for kinases, including OSR-1 and SPAK [28]. The large intracellular C-terminus folds into an alternating β-strand α-helix bundle [29] that controls dimerization of the protein [30], membrane trafficking [31,32], and likely serves important roles in the regulation of transport activity [33▪]. The nine hypertension resistance variants affect the residues in all of these regions, but most of them occur within the transmembrane domains.

FIGURE 3

FIGURE 3

Monette et al.[15] and Acunna et al.[16] found that seven of the nine variants reduced transporter function under basal conditions (six of nine) or activating conditions (one of nine, P254A). The mutagenic effects were qualitatively similar whether the studies were performed in Xenopus oocytes or HEK cells, providing confidence in the observations. It remains uncertain why two of the mutations (P348L and Y1070C) did not markedly alter function, but results with the gating mutants in the ROMK channel illustrate that deleterious effects of some mutations may be conditionally manifested, depending on cell-specific factors or certain negative regulatory activity.

The most severe loss-of-function mutants (R302W and L505V) exhibit a profound decrease in plasma membrane expression, accumulating within an intracellular compartment, likely the ER [15]. These mutants appear to be targeted for degradation by ERAD, similar to the ROMK trafficking mutants. Again, this is a common mechanism for processing misfolded transmembrane proteins and has been observed with other Bartter's mutations in NKCC2 [12]. Interestingly, the two variants exhibit different responses to low temperature-induced adjustments of membrane folding and ER quality control, suggesting that the two mutants are recognized as defective at different steps in the maturation process. Perhaps this should not be so surprising given the different location of the affected residues. R302 is situated at a transmembrane–extracellular interface, whereas L505V projects into the cytoplasmic domain from the intracellular side of a different transmembrane helix.

The T235M mutation also reduced expression at the cell surface membrane, but the effect was much more mild than other trafficking mutants [15]. It remains to be determined whether T235M is a substrate for ERAD, but the mutant localizes near the cell surface rather than the ER, suggesting other mis-trafficking processes may be at play. A peripheral protein quality-control system for removing unfolded cystic fibrosis transmembrane conductance regulator (CFTR) from the cell surface has recently been reported [34]. It will be interesting to learn whether the T235M mutant is processed in a similar way.

The other functional mutations affect regulation and ion translocation processes. Two of the mutants, P254A and N399S, exhibited a blunted activation response to low intracellular chloride [15]. Normally, low chloride stimulates NKCC2 ion transport by promoting the phosphorylation of three highly conserved threonines in the N-terminus through activation of a WNK-SPAK/OSR-1 kinase network [35]. The affected residues, not a part of the kinase docking and phosphorylation sites in NKCC2, are positioned at the intracellular ends of two adjacent transmembrane helices. Monette et al.[15] speculated that the residues are well positioned to serve as a docking site for the regulatory N-terminus, allowing phosphorylation to be translated to transport-dependent conformational changes in the transmembrane ion translocation pathway.

Transport measurements of extracellular ion-dependence revealed that one variant, P569H, exhibited a markedly lower affinity for Na compared to the wild-type NKCC2 [15]. Such a change in Na kinetics would cause a strikingly decreased transport flux rate, especially in the cortical thick ascending limb where the tubular fluid becomes dilute. This observation reinforces an important structure–function relationship. Homology modeling places the residue in the 10th transmembrane domain, which contributes to the cation translocation pathway in other APC superfamily transporters [36].

Back to Top | Article Outline

HYPERTENSION RESISTANCE VARIANTS IN NCC

NCC, a member of the electroneutral cation–chloride cotransporter family (gene name SLC12A3), is responsible for reabsorbing sodium and chloride in the distal convoluted tubule, and is the molecular target of thiazide diuretics [26]. Composed of 12 transmembrane helixes, it shares structural homology with NKCC2 (Figure 3a). The hypertension resistance variants are scattered throughout the structure. Careful measurements of transport in Xenopus oocytes revealed that all five variants reduce basal activity of NCC to variable degrees [16].

Of the NCC variants, the S186F mutation causes the most severe reduction in activity and is the only variant to reduce NCC protein abundance [16]. Although measurements of cell-surface expression have not been performed, this mutant fails to undergo proper N-linked glycosylation, consistent with mistrafficking or misprocessing at an early step in the secretory pathway. On the basis of the phenotype, it seems likely that the S186F variant is misfolded, and a substrate for ERAD. Recent studies indicate that Gitelman's disease-causing mutations that impair NCC biogenesis also fail to escape ERAD as efficiently as the wild-type protein [37,38▪]. Multichaperone complexes, Hsp70, Hsp40, and CHIP, have recently been implicated in selecting these misfolded NCC for ERAD [38▪].

The precise mechanisms driving the loss of function in the four other rare hypertension resistance variants await further characterization. None of these alter protein abundance. Moreover, each variant is activated by WNK3 or intracellular chloride depletion to the same extent as the wild-type transporter, making it unlikely that faulty phospho-dependent regulation contributes to the loss of function.

Back to Top | Article Outline

CONCLUSION

Rare hypertension resistance mutations in NKCC2, NCC, and ROMK alter the transport function by diverse mechanisms, including changing transporter kinetics, or by altering regulation, trafficking, and biogenesis. Nevertheless, they all confer the same low BP phenotype and resistance to hypertension. The new observations demonstrate that common traits such as BP variation and hypertension susceptibility can have disparate genetic origins when different rare mutations produce the same functional effect even when vastly different mechanisms are involved.

Back to Top | Article Outline

Acknowledgements

This work was funded in part by the grants DK63049 and DK54231 from the National Institutes of Health, National Institute of Diabetes, and Digestive and Kidney Diseases.

Back to Top | Article Outline

Conflicts of interest

P.A.W. served as a paid consultant for Pfizer and Bristol Myers Squib in the last year.

Back to Top | Article Outline

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

  • ▪ of special interest
  • ▪▪ of outstanding interest
Back to Top | Article Outline

REFERENCES

1. Salvi E, Kutalik Z, Glorioso N, et al. Genomewide association study using a high-density single nucleotide polymorphism array and case–control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension 2012; 59:248–255.
2. Ehret GB, Munroe PB, Rice KM, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478:103–109.
3. Wain LV, Verwoert GC, O’Reilly PF, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet 2011; 43:1005–1011.
4. Newton-Cheh C, Johnson T, Gateva V, et al. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet 2009; 41:666–676.
5. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009; 41:677–687.
6. Wang Y, O’Connell JR, McArdle PF, et al. From the cover: whole-genome association study identifies STK39 as a hypertension susceptibility gene. Proc Natl Acad Sci USA 2009; 106:226–231.
7. Welling PA, Chang YP, Delpire E, et al. Multigene kinase network, kidney transport, and salt in essential hypertension. Kidney Int 2010; 77:1063–1069.
8▪. Xi B, Chen M, Chandak GR, et al. STK39 polymorphism is associated with essential hypertension: a systematic review and meta-analysis. PLoS One 2013; 8:e59584.

A large meta-analysis confirms the significant association of STK39 (SPAK) polymorphism with susceptibility to hypertension, supporting a role of a multigene kinase network [7] and altered renal salt handling in essential hypertension.

9. Goldstein DB. Common genetic variation and human traits. N Engl J Med 2009; 360:1696–1698.
10▪▪. Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491:56–65.

This resource enables the analysis of common and low-frequency variants in individuals from diverse populations.

11. Ji W, Foo JN, O’Roak BJ, et al. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet 2008; 40:592–599.
12. Seyberth HW, Schlingmann KP. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol 2011; 26:1789–1802.
13. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331:768–772.
14. Fang L, Li D, Welling PA. Hypertension resistance polymorphisms in ROMK (Kir1.1) alter channel function by different mechanisms. Am J Physiol Renal Physiol 2010; 299:F1359–F1364.
15. Monette MY, Rinehart J, Lifton RP, et al. Rare mutations in the human Na–K–Cl cotransporter (NKCC2) associated with lower blood pressure exhibit impaired processing and transport function. Am J Physiol Renal Physiol 2011; 300:F840–F847.
16. Acuna R, Martinez-de-la-Maza L, Ponce-Coria J, et al. Rare mutations in SLC12A1 and SLC12A3 protect against hypertension by reducing the activity of renal salt cotransporters. J Hypertens 2011; 29:475–483.
17. Welling PA, Ho K. A comprehensive guide to the ROMK potassium channel: form and function in health and disease. Am J Physiol Renal Physiol 2009; 297:F849–F863.
18. Lorenz JN, Baird NR, Judd LM, et al. Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome. J Biol Chem 2002; 277:37871–37880.
19. Lukacs GL, Verkman AS. CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med 2012; 18:81–91.
20. Brodsky JL. Cleaning up: ER-associated degradation to the rescue. Cell 2012; 151:1163–1167.
21. Ma D, Taneja TK, Hagen BM, et al. Golgi export of the Kir2.1 channel is driven by a trafficking signal located within its tertiary structure. Cell 2011; 145:1102–1115.
22. Huang CL, Feng S, Hilgemann DW. Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature 1998; 391:803–886.
23. Lopes CM, Zhang H, Rohacs T, et al. Alterations in conserved Kir channel–PIP2 interactions underlie channelopathies. Neuron 2002; 34:933–944.
24. Whorton MR, MacKinnon R. Crystal structure of the mammalian GIRK2 K+ channel and gating regulation by G proteins, PIP2, and sodium. Cell 2011; 147:199–208.
25. Hansen SB, Tao X, MacKinnon R. Structural basis of PIP2 activation of the classical inward rectifier K+ channel Kir2.2. Nature 2011; 477:495–498.
26. Gagnon KB, Delpire E. Physiology of SLC12 transporters: lessons from inherited human genetic mutations and genetically engineered mouse knockouts. Am J Physiol Cell Physiol 2013; 304:C693–C714.
27. Gao X, Lu F, Zhou L, et al. Structure and mechanism of an amino acid antiporter. Science 2009; 324:1565–1568.
28. Gagnon KB, England R, Delpire E. A single binding motif is required for SPAK activation of the Na–K–2Cl cotransporter. Cell Physiol Biochem 2007; 20:131–142.
29. Warmuth S, Zimmermann I, Dutzler R. X-ray structure of the C-terminal domain of a prokaryotic cation–chloride cotransporter. Structure 2009; 17:538–546.
30. Parvin MN, Gerelsaikhan T, Turner RJ. Regions in the cytosolic C-terminus of the secretory Na(+)–K(+)–2Cl(-) cotransporter NKCC1 are required for its homodimerization. Biochemistry 2007; 46:9630–9637.
31. Zaarour N, Demaretz S, Defontaine N, et al. A highly conserved motif at the COOH terminus dictates endoplasmic reticulum exit and cell surface expression of NKCC2. J Biol Chem 2009; 284:21752–21764.
32. Carmosino M, Gimenez I, Caplan M, et al. Exon loss accounts for differential sorting of Na–K–Cl cotransporters in polarized epithelial cells. Mol Biol Cell 2008; 19:4341–4351.
33▪. Monette MY, Forbush B. Regulatory activation is accompanied by movement in the C terminus of the Na–K–Cl cotransporter (NKCC1). J Biol Chem 2012; 287:2210–2220.

This study provides the first direct evidence that regulation of a SLC12 family member involves large movements of C-termini of a dimeric cotransporter, providing a model for understanding the conformational changes required for transport.

34. Okiyoneda T, Barriere H, Bagdany M, et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 2010; 329:805–810.
35. Ponce-Coria J, San-Cristobal P, Kahle KT, et al. Regulation of NKCC2 by a chloride-sensing mechanism involving the WNK3 and SPAK kinases. Proc Natl Acad Sci USA 2008; 105:8458–8463.
36. Gao X, Zhou L, Jiao X, et al. Mechanism of substrate recognition and transport by an amino acid antiporter. Nature 2010; 463:828–832.
37. Needham PG, Mikoluk K, Dhakarwal P, et al. The thiazide-sensitive NaCl cotransporter is targeted for chaperone-dependent endoplasmic reticulum-associated degradation. J Biol Chem 2011; 286:43611–43621.
38▪. Donnelly BF, Needham PG, Snyder AC, et al. Hsp70 and Hsp90 multichaperone complexes sequentially regulate thiazide-sensitive cotransporter endoplasmic reticulum-associated degradation and biogenesis. J Biol Chem 2013; 288:13124–13135.
Keywords:

blood pressure; hypertension; ROMK/KCNJ1/Kir1.1; kidney; loop-diuretic; NKCC2/SLC12A1; salt; SLC12A3; thiazide

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.